D.E. Shaw & Co
CNTA

D.E. Shaw & Co’s Centessa Pharmaceuticals CNTA Stock Holding History

D.E. Shaw & Co’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.6M Sell
643,808
-187,828
-23% -$4.8M 0.02% 1001
2025
Q4 		$20.8M Buy
831,636
+767,247
+1,192% +$19.4M 0.01% 1223
2025
Q3 		$1.56M Buy
64,389
+48,625
+308% +$864K ﹤0.01% 3157
2025
Q2 		$207K Buy
+15,764
New +$200K ﹤0.01% 4042
2024
Q4 		– Sell
-48,078
Closed -$769K – 4458
2024
Q3 		$769K Buy
+48,078
New +$589K ﹤0.01% 3447
2021
Q4 		– Sell
-12,420
Closed -$207K – 5447
2021
Q3 		$207K Buy
+12,420
New +$257K ﹤0.01% 4553

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

D.E. Shaw & Co's CNTA Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Centessa Pharmaceuticals (CNTA) stake by 23% in Q1 2026, selling an estimated $4.8M and leaving 643,808 shares worth $25.6M. The position accounts for 0.02% of the portfolio, ranked #1001.

D.E. Shaw & Co first reported a position in CNTA in Q3 2021 and has held it in 6 quarters since. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • D.E. Shaw & Co held 643,808 shares of Centessa Pharmaceuticals worth $25.6M as of Q1 2026.
  • D.E. Shaw & Co sold 187,828 Centessa Pharmaceuticals shares in Q1 2026, an estimated $4.8M.
  • Centessa Pharmaceuticals made up 0.02% of D.E. Shaw & Co's portfolio in Q1 2026, its #1001 holding.
  • D.E. Shaw & Co first reported a position in Centessa Pharmaceuticals in Q3 2021 and has held it in 6 quarters since.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.